Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

被引:74
作者
Ganot, Nitzan [1 ]
Meker, Sigalit [1 ]
Reytman, Lilia [1 ]
Tzubery, Avia [1 ]
Tshuva, Edit Y. [1 ]
机构
[1] Hebrew Univ Jerusalem, Inst Chem, IL-91905 Jerusalem, Israel
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2013年 / 81期
基金
欧洲研究理事会;
关键词
Medicine; Issue; 81; Inorganic Chemicals; Therapeutics; Metals and Metallic Materials; anticancer drugs; cell viability; cisplatin; metal complex; cytotoxicity; HT-29; metal-based drugs; MTT assay; titanium (IV); vanadium (V); CANCER-TREATMENT; TITANIUM COMPLEXES; ANTITUMOR-ACTIVITY; LIGANDS; HYDROLYSIS; VANADIUM; INSIGHTS; AGENTS; DRUGS;
D O I
10.3791/50767
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Titanium (IV) and vanadium (V) complexes are highly potent anticancer agents. A challenge in their synthesis refers to their hydrolytic instability; therefore their preparation should be conducted under an inert atmosphere. Evaluation of the anticancer activity of these complexes can be achieved by the MTT assay. The MTT assay is a colorimetric viability assay based on enzymatic reduction of the MTT molecule to formazan when it is exposed to viable cells. The outcome of the reduction is a color change of the MTT molecule. Absorbance measurements relative to a control determine the percentage of remaining viable cancer cells following their treatment with varying concentrations of a tested compound, which is translated to the compound anticancer activity and its IC50 values. The MTT assay is widely common in cytotoxicity studies due to its accuracy, rapidity, and relative simplicity. Herein we present a detailed protocol for the synthesis of air sensitive metal based drugs and cell viability measurements, including preparation of the cell plates, incubation of the compounds with the cells, viability measurements using the MTT assay, and determination of IC50 values.
引用
收藏
页数:6
相关论文
共 31 条
[1]  
Ahmadian Somaieh, 2009, J Vis Exp, DOI 10.3791/1191
[2]  
ALLEY MC, 1988, CANCER RES, V48, P589
[3]   New trends for metal complexes with anticancer activity [J].
Bruijnincx, Pieter C. A. ;
Sadler, Peter J. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (02) :197-206
[4]   Bioinorganic Chemistry of Titanium [J].
Buettner, Katherine M. ;
Valentine, Ann M. .
CHEMICAL REVIEWS, 2012, 112 (03) :1863-1881
[5]   Antitumor titanium compounds [J].
Caruso, F ;
Rossi, M .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (01) :49-60
[6]   Anticancer titanium agents [J].
Caruso, F ;
Rossi, M ;
Pettinari, C .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (06) :969-979
[7]   Group 4 complexes with aminebisphenolate ligands and their application for the ring opening polymerization of cyclic esters [J].
Chmura, Amanda J. ;
Davidson, Matthew G. ;
Jones, Matthew D. ;
Lunn, Matthew D. ;
Mahon, Mary F. ;
Johnson, Anthony F. ;
Khunkamchoo, Prasert ;
Roberts, Sian L. ;
Wong, Stephen S. F. .
MACROMOLECULES, 2006, 39 (21) :7250-7257
[8]   RAPID COLORIMETRIC ASSAY FOR CELL-GROWTH AND SURVIVAL - MODIFICATIONS TO THE TETRAZOLIUM DYE PROCEDURE GIVING IMPROVED SENSITIVITY AND RELIABILITY [J].
DENIZOT, F ;
LANG, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 89 (02) :271-277
[9]  
Desoize B, 2004, ANTICANCER RES, V24, P1529
[10]  
DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595